Despite the fact that Astra Zeneca will initially not be able to deliver the number that was originally promised to the EU countries, Richard Bergström is optimistic about the future.
At a meeting on Monday, he hopes to get an answer on whether the company can also deliver vaccines from facilities other than those affected by problems in Belgium.
- The question is whether we can get vaccines from facilities in the UK and the US.
They have not answered that yet, we will see, says Richard Bergström.
- There is no doubt that we get what we ordered, the question is when.
Sweden receives 7.5 million doses and according to the contract, everything must be delivered by the end of June.
In the worst case, this will be postponed to the third quarter.
But I am hopeful that with the help of the facilities in the UK and the US we will be able to recover the loss.
"Recommendations certainly short-lived"
Although the European Medicines Agency (EMA) has approved Astra Zeneca's vaccine, questions remain about its effectiveness among people over 65 years of age.
Something that has been pointed out by both France and Germany, who believe that too little is known about the vaccine at present.
As early as next week, the Swedish Public Health Agency is expected to present its recommendations regarding the vaccine, despite the deficient data.
But according to Richard Bergström, the messages can change quickly.
"In just a few months, there will be a large American study on Astra Zeneca's vaccine, which involves many elderly people," he says.
- Then we get an answer to the question of what the protective effect is and can straighten out that question mark.
The public health authority has said that they will make recommendations on Monday - they will certainly be short-lived.